Support is likely to develop in the $38-$34 area.
Buyers of classic senior growth stocks have returned to their old flames.
Technical indicators suggest GSK can see further significant gains in 2017.
The failure of ACA repeal isn't the only troublesome sign for the markets.
Particularly if Trump lets the sleeping (health-care) dog lie and gets back to deregulation and tax reform.
Answering questions from the Biotech Mailbag on FLXN and SGYP.
Failure of health-care bill barely causes a ripple.
Answering questions from the Biotech Mailbag on FLXN and SGYP.
The health care debate isn't about health care. It is about leadership and deal making.


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.